Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

FRANKFURT: European stocks logged their biggest one-day drop in over three months on Friday, at the end of a busy week as ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

The Trump administration is evaluating a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, ...